anthracycline cardiomyopathy
Pronunciation: AN-thra-SYE-kleen kar-dee-oh-my-OP-athy
Heart muscle damage caused by anthracycline chemotherapy drugs, leading to reduced cardiac function.
Full Definition
Anthracycline cardiomyopathy is a dose-dependent cardiotoxicity that can occur during or after treatment with anthracycline chemotherapy agents such as doxorubicin, daunorubicin, or epirubicin. It results from oxidative damage to cardiac myocytes and can manifest as acute, subacute, or chronic cardiomyopathy. The condition may be reversible in early stages but can progress to irreversible heart failure. Regular cardiac monitoring with echocardiograms or MUGA scans is standard practice during anthracycline therapy.
Usage
Usage note: Hyphenate 'anthracycline-cardiomyopathy' when used as a compound modifier.
In Context
- "Baseline echocardiography is required before starting therapy due to anthracycline cardiomyopathy risk." — Protocol document
- "The patient developed anthracycline cardiomyopathy after cumulative doxorubicin dose of 300 mg/m²." — Cardiology consultation